Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
HOUSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to...
Brain
Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial...
Annexon Biosciences to Present at the Bank of America Health Care Conference
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform...
Zeto Announces Expert Jury for Its EEG Clinical Trial Sponsorship Program
The selected clinical research projects will be publicly announced by June 10th, 2024SANTA CLARA, CA / ACCESSWIRE / May 7,...
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLYGOTHENBURG, SE / ACCESSWIRE / May 7, 2024...
Greene Concepts and Tocca Life Holdings Join Forces Within $4.5 Trillion U.S. Healthcare Industry to Increase Vitality Nationwide
Marion, North Carolina--(Newsfile Corp. - May 7, 2024) - Greene Concepts Inc. (OTC PINK: INKW) and Tocca Life Holdings, Inc....
FSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia
TORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical...
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
AI-informed drug design enabled approval to dose within one year of project initiation Data highlight use of AI to engineer...
Cogent Biosciences Reports First Quarter 2024 Financial Results
SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025...
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals...
Masimo Receives FDA Clearance for Stork™ Over-the-Counter (OTC) Baby Monitoring System
With This Clearance, Stork Provides Continuous Monitoring of Oxygen Saturation, Pulse Rate, and Skin Temperature, with Alarms, for Babies up...
Nanomerics Wins the United Kingdom King’s Award for Enterprise Innovation 2024
Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had been awarded the prestigious King's Award for Enterprise...
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics...
IRLAB: Invitation to the Interim Report for Q1 2024 Presentation and Webcast
GOTHENBURG, SWEDEN / ACCESSWIRE / May 6, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, May 6, 2024 - IRLAB Therapeutics...
Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has...
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights...
Cerevance Achieves First Milestone in Research Collaboration with Merck
BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system...
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces...
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable...
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low...